RIFAXIMINA RIDUCE LA INFIAMMAZIONE DI PROVENIENZA INTESTINALE ! IL TRIAL “RIFSYS” SUL J. OF HEPATOLOGY (FREE).
Rifaximin-a reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial Vishal C. Patel et al. Highlights Rifaximin reduced gut-derived systemic inflammation by suppressing oralisation of the gut microbiome. Rifaximin suppressed mucin-degrading species rich in sialidase, e.g. Streptococcus and Veillonella spp. Rifaximin promotes an intestinal environment augmenting re-…